Drugmaker Johnson & Johnson asked the US Food and Drug Administration (FDA) on Tuesday to authorize booster shots of its Covid-19 vaccine for people over the age of 18.
“Our clinical program has found that a booster of our Covid-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent,” said Mathai Mammen, global head of research and development at J&J.
J&J said that when a booster was given six months after the first shot, “antibody levels increased nine-fold one week after the booster and continued to climb to 12-fold higher four weeks after the booster,” irrespective of age.
“We look forward to our discussions with the FDA and other health authorities to support their decisions regarding boosters,” Mammen said.
President Joe Biden‘s administration announced plans in August for Americans vaccinated with the Pfizer and Moderna mRNA vaccines to get third shots.
Last month, the CDC recommended booster shots for tens of millions of Americans that received the Pfizer COVID-19 vaccine, including those 65 years and older, immunocompromised individuals, and those with an “increased risk for COVID-19 exposure and transmission because of an occupational or institutional setting.”
Biden personally received a Covid-19 vaccine booster shot last month and told Americans still resisting vaccination they are damaging the country.
The FDA said Tuesday its advisory committee would meet on October 14 to discuss an emergency use authorization of Moderna booster shots and on October 15 to discuss the J&J booster.